150 related articles for article (PubMed ID: 36647200)
1. Direct Incorporation of Expert Opinion into Parametric Survival Models to Inform Survival Extrapolation.
Cooney P; White A
Med Decis Making; 2023 Apr; 43(3):325-336. PubMed ID: 36647200
[TBL] [Abstract][Full Text] [Related]
2. The Role of Expert Opinion in Projecting Long-Term Survival Outcomes Beyond the Horizon of a Clinical Trial.
Willigers BJA; Ouwens M; Briggs A; Heerspink HJL; Pollock C; Pecoits-Filho R; Tangri N; Kovesdy CP; Wheeler DC; Garcia Sanchez JJ
Adv Ther; 2023 Jun; 40(6):2741-2751. PubMed ID: 37071317
[TBL] [Abstract][Full Text] [Related]
3. Development of a practical approach to expert elicitation for randomised controlled trials with missing health outcomes: Application to the IMPROVE trial.
Mason AJ; Gomes M; Grieve R; Ulug P; Powell JT; Carpenter J
Clin Trials; 2017 Aug; 14(4):357-367. PubMed ID: 28675302
[TBL] [Abstract][Full Text] [Related]
4. Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trials in Health Technology Assessment.
Che Z; Green N; Baio G
Med Decis Making; 2023 Apr; 43(3):299-310. PubMed ID: 36314662
[TBL] [Abstract][Full Text] [Related]
5. Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.
Chaudhary MA; Edmondson-Jones M; Baio G; Mackay E; Penrod JR; Sharpe DJ; Yates G; Rafiq S; Johannesen K; Siddiqui MK; Vanderpuye-Orgle J; Briggs A
Med Decis Making; 2023 Jan; 43(1):91-109. PubMed ID: 36259353
[TBL] [Abstract][Full Text] [Related]
6. Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma.
Ayers D; Cope S; Towle K; Mojebi A; Marshall T; Dhanda D
BMC Med Res Methodol; 2022 Oct; 22(1):272. PubMed ID: 36243687
[TBL] [Abstract][Full Text] [Related]
7. Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.
Sweeting MJ; Rutherford MJ; Jackson D; Lee S; Latimer NR; Hettle R; Lambert PC
Med Decis Making; 2023 Aug; 43(6):737-748. PubMed ID: 37448102
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
Federico Paly V; Kurt M; Zhang L; Butler MO; Michielin O; Amadi A; Hernlund E; Johnson HM; Kotapati S; Moshyk A; Borrill J
MDM Policy Pract; 2022; 7(1):23814683221089659. PubMed ID: 35356551
[TBL] [Abstract][Full Text] [Related]
9. Modeling of experts' divergent prior beliefs for a sequential phase III clinical trial.
Moatti M; Zohar S; Facon T; Moreau P; Mary JY; Chevret S
Clin Trials; 2013 Aug; 10(4):505-14. PubMed ID: 23820061
[TBL] [Abstract][Full Text] [Related]
10. What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma.
Klijn SL; Fenwick E; Kroep S; Johannesen K; Malcolm B; Kurt M; Kiff C; Borrill J
Pharmacoeconomics; 2021 Mar; 39(3):345-356. PubMed ID: 33428174
[TBL] [Abstract][Full Text] [Related]
11. Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial.
Turner RM; Turkova A; Moore CL; Bamford A; Archary M; Barlow-Mosha LN; Cotton MF; Cressey TR; Kaudha E; Lugemwa A; Lyall H; Mujuru HA; Mulenga V; Musiime V; Rojo P; Tudor-Williams G; Welch SB; Gibb DM; Ford D; White IR;
BMC Med Res Methodol; 2022 Feb; 22(1):49. PubMed ID: 35184739
[TBL] [Abstract][Full Text] [Related]
12. SurvInt: a simple tool to obtain precise parametric survival extrapolations.
Gallacher D
BMC Med Inform Decis Mak; 2024 Mar; 24(1):76. PubMed ID: 38486175
[TBL] [Abstract][Full Text] [Related]
13. Prediction models for clustered data with informative priors for the random effects: a simulation study.
Ni H; Groenwold RHH; Nielen M; Klugkist I
BMC Med Res Methodol; 2018 Aug; 18(1):83. PubMed ID: 30081875
[TBL] [Abstract][Full Text] [Related]
14. Extrapolation of Survival Curves from Cancer Trials Using External Information.
Guyot P; Ades AE; Beasley M; Lueza B; Pignon JP; Welton NJ
Med Decis Making; 2017 May; 37(4):353-366. PubMed ID: 27681990
[TBL] [Abstract][Full Text] [Related]
15. Integrating expert opinions with clinical trial data to analyse low-powered subgroup analyses: a Bayesian analysis of the VeRDiCT trial.
Thirard R; Ascione R; Blazeby JM; Rogers CA
BMC Med Res Methodol; 2020 Dec; 20(1):300. PubMed ID: 33302878
[TBL] [Abstract][Full Text] [Related]
16. A comparison of two methods for expert elicitation in health technology assessments.
Grigore B; Peters J; Hyde C; Stein K
BMC Med Res Methodol; 2016 Jul; 16():85. PubMed ID: 27456844
[TBL] [Abstract][Full Text] [Related]
17. Expert opinion as priors for random effects in Bayesian prediction models: Subclinical ketosis in dairy cows as an example.
Ni H; Klugkist I; van der Drift S; Jorritsma R; Hooijer G; Nielen M
PLoS One; 2021; 16(1):e0244752. PubMed ID: 33444385
[TBL] [Abstract][Full Text] [Related]
18. How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017.
Gallacher D; Auguste P; Connock M
Int J Technol Assess Health Care; 2019 Jan; 35(2):160-167. PubMed ID: 31017564
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs.
van Oostrum I; Ouwens M; Remiro-Azócar A; Baio G; Postma MJ; Buskens E; Heeg B
Value Health; 2021 Sep; 24(9):1294-1301. PubMed ID: 34452709
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
